An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Renal Cell Cancer
Both
Renal Cell Cancer
Trial Information
An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Advanced and/or metastatic renal cell carcinoma
- Receiving first-line treatment with Avastin and interferon alpha-2a according to
standard of care and current local label
- At least one measurable and non-measurable lesion according to RECIST criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Adequate bone marrow, renal and liver function
Exclusion Criteria:
- Contraindications to Avastin and/or interferon alpha-2a as per local label
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Safety: Incidence of adverse events
Outcome Time Frame:
approximately 4 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
India: Directorate General of Health Services - Drugs Controller General
Study ID:
ML25251
NCT ID:
NCT01351571
Start Date:
August 2010
Completion Date:
August 2011
Related Keywords:
- Renal Cell Cancer
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
